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Introduction
The guidelines project is a joint initiative of the Associac¸ão
Médica Brasileira and the Conselho Federal de Medicina. It aims
to bring together information in medicine to standardize
conduct in order to help decision-making during treatment.
The data contained in this article were prepared by and
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reserved.are recommended by the Associac¸ão Brasileira de Hematologia,
Hemoterapia e Terapia Celular (ABHH). Even so, all possible con-
ducts should be evaluated by the physician responsible for
treatment depending on the patient’s setting and clinical sta-
tus. de Medicina de Ribeirão Preto, Universidade de São Paulo (USP),
This article presents the guidelines for the treatment of
acute myeloid leukemia (AML). The expert group of the ABHH
mainly focused on issues related to chemotherapy and the
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
oter. 
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election of patient subgroups for which there are specific
ecommendations for treatment. The indications, but not the
ctual treatment protocols for bone marrow transplantation,
ere analyzed.
escription  of  the  method  used  to  gather
vidence
hese Guidelines were drafted by elaborating 12 clinically
elevant questions related to the treatment of AML. The
uestions were structured using the Patient/Problem, Inter-
ention, Comparison and Outcome (PICO) system, allowing
he generation of evidence search strategies in the key sci-
ntific databases (MEDLINE PubMed, Lilacs, SciELO, Embase,
ochrane Library, Premedline via OVID). The data recov-
red was critically analyzed using discriminatory instruments
scores) according to the type of evidence – JADAD for ran-
omized clinical trials and the Newcastle Ottawa scale for
on-randomized studies. After identifying studies that poten-
ially substantiate recommendations, the level of evidence
nd degree of recommendation were calculated using the
xford Classification.1
ummary  of  the  degree  of  recommendation
nd  level  of  evidence
A: Major experimental and observational studies
B: Minor experimental and observational studies
C: Case reports (non-controlled studies)
D: Opinion without critical evaluation based on consensus,
physiological studies or animal models
ims
he aim of these guidelines is to contribute to decision making
n the treatment of AML.
hich  anthracycline  agent  is  the  most  effective
n  inducing  remission  of  acute  myeloid
eukemia?
P – Patients undergoing induction treatment for AML
I – Anthracycline agent (daunorubicin, doxorubicin, idaru-
bicin)
C –
O – Complete remission rate, overall survival, and disease-
free survival
Two different induction treatments were compared in
nder 18-year-old patients (mean age: 7.9 years) with de novo
ML: cytarabine, idarubicin and etoposide (AIE) and cytara-
ine, daunorubicin and etoposide (EDA). The AIE regimen
as cytarabine (100 mg/m2/day) as a continuous infusion on
ays 1 and 2 and 30-min infusions on Days 3–8, idarubicin
12 mg/m2/day) as 30-min infusions on Days 3–5 and etopo-
ide (150 mg/m2/day) as 120-min infusions on Days 6–8. The2 0 1 6;3 8(1):58–74 59
EDA regimen was cytarabine (100 mg/m2/day) as continuous
infusions on Days 1 and 2, and 30-min infusions on Days 3–8),
daunorubicin (30 mg/m2) as 30-min infusions every 12 h on
Days 3–5) and etoposide (150 mg/m2/day) as 120-min infusions
on Days 6–8. After the exclusion of patients with myelosar-
coma, secondary AML, myelodysplastic syndrome (MDS) and
Down syndrome, and with 22% of patients having favorable
karyotypes, a significantly higher percentage of patients had
blast counts ≤5% by the 15th day after induction with the AIE
regimen compared to the ADE regimen (83% vs. 69%, respec-
tively; p-value = 0.01) (A).2
There was no significant differences between the groups
in respect to complete remission (CR) (87% for AIE and for
ADE), deaths (5% for AIE and 3% for ADE; p-value = 0.41), car-
diac or hematologic toxicity or for the presence of grade 3 and
4 mucositis after induction therapy (A).2
On analyzing under 65-year-old adult patients with de novo
AML stratified into two induction treatment groups: idarubicin
(12 mg/m2/day) for three days or daunorubicin (50 mg/m2/day)
for five days both associated with cytarabine (100 mg/m2/day)
by 24-h continuous infusions for seven days, the CR was
similar after the first cycle (64.1% vs. 61.1%, respectively; p-
value = 0.39). The same regimen was repeated at 3–4-week
intervals when patients did not achieve CR after the first cycle
with the overall CR rate increasing to 77.9% (78.2% for idaru-
bicin vs. 77.5% for daunorubicin; p-value = 0.79). Although few
patients were characterized as M6 by the French-American-
British classification (FAB) system (3.12%), this group responds
better to the idarubicin regimen after the first cycle [odds ratio
(OR): 78% vs. 38%; p-value = 0.037]. However, there is no signif-
icant difference between the two anthracyclines in respect to
the other FAB subtypes of AML, cytogenetic risk groups, age,
the initial white blood cell count, the percentage of positive
myeloperoxidase blasts or performance status (A).3
Induction treatment with daunorubicin (50 mg/m2/day),
mitoxantrone (12 mg/m2/day) or idarubicin (10 mg/m2/day) on
Days 1, 3 and 5 associated with cytarabine (100 mg/m2/day) as
a ten-day continuous infusion and etoposide (100 mg/m2/day)
as a 1-h infusion for five days results in a CR of 63.6% in 15-
to 60-year-old patients with primary or secondary AML. There
is no evidence of serious cardiac, pulmonary, neurologic or
metabolic comorbidities or uncontrolled infections and nor-
mal  hepatic and renal function with this regimen. In cases of
partial response, a second cycle is performed using the same
regimen as the first cycle and the CR increases to 68.5% with
no significant differences between the treatment arms (mitox-
antrone vs. daunorubicin: p-value = 0.63; and daunorubicin vs.
idarubicin: p-value = 0.49) (A).4
Patients with de novo AML or secondary AML  due to MDS
and normal heart function stratified into three age groups
(15–50 years, 51–60 years and over 60 years old) were evalu-
ated in respect to induction regimens. The use of idarubicin
(IDA – 12–13 mg/m2/day for three days) or daunorubicin (DNR
– 45 mg/m2/day for three days), both in combination with
cytarabine (100 mg/m2/day by seven-day continuous infusion)
were compared. A second cycle using the same drug was
administered if there were more  than 5% leukemic blasts in
the bone marrow at Day 14. There was a better, albeit not nec-
essarily statistically significant, CR for the idarubicin group
mote
cytarabine (100 mg/m /day) as continuous infusions on Days
260  rev bras hematol he
(70–74% vs. 57–59%; p-value = 0.032–0.09). When evaluated sep-
arately, there was no significant difference between the groups
after the first and after the second cycle. When the evaluation
was performed for the three age groups, lower CR rates were
observed as the age increased (15–50 years: 86–91% vs. 70–80%;
51–60 years: 67–71% vs. 45–65%; >60 years: 50–68% vs. 44–53%
for the IDA and DNR groups, respectively). There was no signif-
icant difference in hematologic and non-hematologic toxicity
for both groups regardless of age (A).5–8
On comparing daunorubicin (DNR – 80 mg/m2/day for three
days), idarubicin (IDA4 – 12 mg/m2/day for four days), and
idarubicin (IDA3 – 12 mg/m2/day for three days), all associated
with cytarabine (200 mg/m2/day as a seven-day continuous
infusion) in 50- to 70-year-old patients, the overall CR was
66%. CR rates of 61%, 67% and 70% were recorded for the
DNR, IDA4 and IDA3 arms, respectively (p-value = 0.25). How-
ever, when patients received a second induction cycle, all with
mitoxantrone (12 mg/m2/day for two days) associated with
cytarabine (1 g/m2 over 1 h every 12 h for four days), the CR
increased to 77%. The difference between the three compar-
ison arms was significant (p-value = 0.04) with the CR being
70%, 78% and 83% for the DNR, IDA4 and IDA3 arms, respec-
tively. The CR was significantly higher in the IDA3 arm when
compared to the high-dose DNR arm (p-value = 0.007), with
a tendency of better rates in the subgroup with unfavorable
cytogenetics (74% vs. 48%; p-value = 0.07). Consequently, the
CR was higher in patients receiving idarubicin than in those
receiving daunorubicin (80% vs. 70%; p-value = 0.03). There
were no significant differences in the mortality rates, length of
hospitalization, cytopenias, grade 3 or 4 infection rates, bleed-
ing episodes or the duration of antibiotic therapy between the
three groups during induction (A).9
Induction therapy for de novo AML  in 55- to 75-year-old
patients using cytarabine (100 mg/m2/day) as a seven-day con-
tinuous infusion associated with idarubicin (8 mg/m2/day) for
five days or daunorubicin (50 mg/m2/day) for three days was
compared. There were no significant differences in the CR
(IDA: 67.9% vs. DNR: 61.1%; p-value = 0.29) or hematologic or
non-hematological toxicity (A).10
In over 65-year-old patients with de novo AML or AML  sec-
ondary to MDS  (FAB: refractory anemia with excess blasts in
transformation – RAEB-T), daunorubicin (45 mg/m2/day) for
four days was compared with idarubicin (9 mg/m2/day) for
four days both associated with cytarabine (200 mg/m2/day) by
a seven-day continuous infusion. After the initial induction
chemotherapy cycle, a second cycle of cytarabine (500 mg/m2)
in a 1-h infusion every 12 h for three days associated with
mitoxantrone (12 mg/m2/day) for two days was administered
when CR was not achieved. The overall CR rate was 57% (53.8%
after the first induction cycle); the CR rate for the DNR arm
was 54% and for the IDA arm it was 59% (p-value = 0.28). The
mortality rate in both groups was 10% (A).11
Three induction therapies were compared in over 55-
year-old treatment-naive AML  patients without serious
heart conditions, and normal liver and kidney function:
daunorubicin (45 mg/m2/day) for three days or idarubicin
(12 mg/m2/day) for three days or mitoxantrone (12 mg/m2/day)
2for three days, associated with cytarabine (100 mg/m /day)
by seven-day continuous infusion. The overall CR rate
was 39.7–42%, with no significant difference between ther. 2 0 1 6;3 8(1):58–74
anthracyclines used. However, when only under 70-year-old
patients of that group were evaluated, the CR of the idaru-
bicin arm was better than the daunorubicin arm (55% vs. 46%,
respectively; p-value = 0.04) (A).12
Recommendations: On comparing the efficacy of induc-
tion therapy using the anthracyclines, idarubicin and
daunorubicin in AML patients of different ages, although
the reduction in the blast count was faster with the first
cycle of idarubicin, there were no significant differences
in the CR or toxicity of the two drugs.
What  dose  (100  mg/m2/day  and  200  mg/m2/day)
of cytarabine  (Ara-C  or  Arabinoside-C)  is  the
most  effective  in  the  induction  therapy  of  acute
myeloid  leukemia  patients?
P – Patients undergoing induction treatment for AML
I – Cytarabine (Ara-C or Arabinoside-C) – 100 mg/m2/day
C – Cytarabine (Ara-C or Arabinoside-C) – 200 mg/m2/day
O – Complete remission rate, overall survival, and disease-
free survival
On comparing induction therapy for AML  patients using
cytarabine (100 mg/m2/day) or cytarabine (200 mg/m2/day) as
a seven-day continuous infusion associated with daunoru-
bicin (45 mg/m2/day) in under 60-year-old patients or
(30 mg/m2/day) in over 60-year-old patients, the CR was 61%
with no significant difference between doses (p-value = 0.29).
There was also no significant difference in the CR rate
when the over and under 60-year-old patients were evalu-
ated separately (p-value = 0.68 vs. p-value = 0.08, respectively).
However, there was a 7% lower risk of death during induc-
tion therapy for the under 60-year-old patients in the group
that received 100 mg/m2/day [needed to harm (NNH): 15; p-
value = 0.04] and a 6% decrease in over 60-year-olds (NNH: 17;
p-value = 0.51). The main cause of death was infections in both
the 100 mg/m2/day and the 200 mg/m2/day groups (A).13
Two induction regimens were evaluated in 18- to 60-
year-old patients with de novo AML. The first group received
cytarabine (200 mg/m2/day) during the first cycle and cytara-
bine (1 g/m2) every 12 h as a 3-h continuous infusion in
a second cycle, and the second group received cytarabine
(1 g/m2) every 12 h in the first cycle and cytarabine (2 g/m2)
every 12 h in the second cycle. There was no significant differ-
ence in CR (34% vs. 35%, respectively) and overall survival (OS)
between the two groups (40% vs. 42%, respectively). The higher
dose of cytarabine resulted in a higher incidence of grade 3 and
4 toxicity, longer hospital stay and longer delays in neutrophil
and platelet engraftment (A).14
Two different induction regimens were compared in AML
patients aged 16–60 years old. The first, TAD cycle was
21 and 2 and then cytarabine (200 mg/m /day) as 30-min
infusions every 12 h on Days 3–8 associated with daunoru-
bicin (60 mg/m2/day) as 30-min infusions on Days 3–5 and
oter. 
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hioguanine (100 mg/m2/day) orally on Days 3 and 9. This
as followed by another cycle using the same doses. The
econd regimen was one TAD cycle, followed by a second
AM cycle with cytarabine (3 g/m2) in 3-h infusions every 12 h
n Days 1–3 associated with mitoxantrone (10 mg/m2/day) in
0-min infusions on Days 3–5. There was no significant dif-
erence between the two groups in respect to the CR (67% vs.
1%, respectively; p-value = 0.072). The times to neutrophil and
latelet engraftment were lower for the group that received
he TAD-TAD regimen than those that received the TAD-HAM
egimen (16 days vs. 20 days, respectively; p-value = 0.0001)
A).15
A continuous seven-day infusion of cytara-
ine (100 mg/m2/day) associated with daunorubicin
50 mg/m2/day) Days 1–3 and etoposide (75 mg/m2/day)
n Days 1–7 was compared with cytarabine (3 g/m2) every
2 h on Days 1, 3, 5 and 7, associated with daunorubicin
50 mg/m2/day) on Days 1–3 and etoposide (75 mg/m2/day) on
ays 1–7. CR was attained in 74% [95% confidence interval (CI):
6–81%] of the group submitted to standard dose cytarabine
nd 71% (95% CI: 63–78%) of the group submitted to high-dose
ytarabine (p-value = 0.7). Significantly more  patients in the
igh-dose cytarabine group discontinued induction ther-
py due to toxicity (1% vs. 9%, respectively; p-value = 0.003)
A).16
The use of cytarabine (10 mg/m2) subcutaneously every 12 h
or 21 days was compared with cytarabine (200 mg/m2/day)
s a seven-day continuous infusion associated with rubida-
one (100 mg/m2/day – derived from daunorubicin) for four
ays as induction therapy in over 65-year-old patients with
e novo AML. The outcomes were CR, partial remission, treat-
ent failure, and death in 32%, 22%, 36% and 10%, respectively
f patients receiving subcutaneous cytarabine, and 52%, 2%,
5% and 31%, respectively of those receiving intensive ther-
py. That is, the number of CR patients and deaths were higher
n the group that received high-dose cytarabine, while partial
emission and treatment failure were more  frequent in those
ubmitted to low-dose cytarabine (p-value <0.001). Grade 3 and
 toxicity, infectious complications and prolonged cytopenias
ere significantly higher in the intensive therapy group (p-
alue <0.01) (A).17
Recommendations: Due to the lower risk of death
using 100 mg/m2/day of cytarabine compared to
200 mg/m2/day of cytarabine in the induction ther-
apy of AML  patients and no significant difference in
the CR between the two groups, the lower dose is more
appropriate. This is true for all age groups.
hat  dose  of  daunorubicin  (45,  60  or
0 mg/m2/day)  is  the  most  effective  for
nduction  therapy  of  acute  myeloid  leukemia  in
oung  patients  (<60  years)?P – Under 60-year-old patients undergoing induction treat-
ment for AML2 0 1 6;3 8(1):58–74 61
I – Daunorubicin (45, 60 or 90 mg/m2/day)
C – Daunorubicin (45, 60 or 90 mg/m2/day)
O – Complete remission rate, overall survival, and disease-
free survival
Over six years, 17- to 60-year-old patients with AML  were
treated with cytarabine (100 mg/m2/day) by seven-day con-
tinuous infusion associated with daunorubicin at doses of
45 mg/m2/day or 90 mg/m2/day for three days. Bone marrow
biopsies were performed between Day 12 and 14 after induc-
tion therapy, and if the patient continued with leukemic blasts
in the bone marrow, a second cycle was administered with the
same doses of cytarabine and daunorubicin (45 mg/m2/day).
The overall CR rate was 63.9% (95% CI: 59.9–67.8), 57.3% in
the group that received a dose of 45 mg/m2 and 70.6% in
the group that received a high dose of daunorubicin (p-value
<0.001). Of the patients in this study, 72% of the 45 mg/m2/day
group and 83.3% of the high-dose group achieved CR after the
first induction cycle (p-value = 0.01); thus only 11.4% achieved
CR after the second cycle of chemotherapy. There was no
significant difference in the rate of hematological and non-
hematological toxicity (grades 3–5) or the death rates during
induction between the two groups (A).18
Two doses of daunorubicin, 45 mg/m2/day and
90 mg/m2/day for three days, associated with cytarabine
(200 mg/m2/day) by seven-day continuous infusion were
compared in a population of 15- to 60-year-old AML  patients.
Patients with CML in the blast phase and those with prom-
yelocytic leukemia were excluded and all participants had
adequate renal and hepatic function and normal heart
function. The CR was superior in the group that received
the high dose of daunorubicin (72% vs. 82.5%; p-value = 0.01)
with a significant difference after the first induction cycle
(56.1% vs. 71.1% for 45 mg/m2 and high-dose, respectively;
p-value = 0.04), and therefore a 15% reduction in the need
to perform a second cycle of chemotherapy. There was
no significant difference regarding the hematological and
non-hematological adverse events between the two groups
(A).19
One study compared daunorubicin (45 mg/m2/day) for
three days, and a second cycle when necessary at the same
dose, with daunorubicin (75 mg/m2/day) for three days, and
a second cycle of 60 mg/m2/day when there were more than
5% of blasts in the bone marrow. All cycles were associ-
ated with cytarabine (100 mg/m2/day) by continuous infusion
and etoposide (100 mg/m2/day) in 30-min infusions, both for
seven days. The participants were 13- to 67-year-old patients
(mean 33 years) with de novo AML. Patients with secondary
AML  or promyelocytic leukemia according to the FAB clas-
sification were excluded, as were patients with severely
impaired heart function. The overall CR was 65%, 58.9% in the
group that received two cycles of 45 mg/m2/day of daunoru-
bicin and 77% in the group that received 75 mg/m2/day and
60 mg/m2/day of daunorubicin (p-value = 0.04). When the CR
was evaluated after the first cycle of chemotherapy, the
result was significantly better in the group that took the
higher dose of daunorubicin (85.1% vs. 60.8%; p-value = 0.02).
There was no significant difference between the two groups
in respect to hematologic and non-hematologic toxicity
(A).20
mote62  rev bras hematol he
Recommendations: In adult patients with AML, high
doses of daunorubicin (60–90 mg/m2/day) associated
with cytarabine (100 or 200 mg/m2/day) increase the CR
rate in induction therapy, both after the first and second
cycles of chemotherapy without increasing the hemato-
logic or non-hematologic toxicity when compared to a
dose of 45 mg/m2/day of daunorubicin.
What  dose  of  daunorubicin  (45,  60  or  90  mg/m2)
is  the  most  effective  for  induction  therapy  of
acute  myeloid  leukemia  in  elderly  patients
(>60 years)?
P – Over 60-year-old patients undergoing induction treat-
ment for AML
I – Daunorubicin (45, 60 or 90 mg/m2)
C – Daunorubicin (45, 60 or 90 mg/m2)
O – Complete remission rate, overall survival, and disease-
free survival
Elderly AML  patients (61–75 years old) not including
patients with the M3  subtype were evaluated using two induc-
tion regimens. All patients had normal liver and kidney
function, no recent history of myocardial infarction or other
severe cardiovascular disease and had no documented active
infection. Cytarabine (100 mg/m2/day) was administered as a
seven-day continuous infusion for all patients but one group
received daunorubicin (45 mg/m2/day) for three days and the
other, liposomal daunorubicin (80 mg/m2/day) for three days
with repeated second cycles using the same doses as the first
cycle if the patient did not achieve CR. Of the patients receiv-
ing the standard dose of daunorubicin, 11.5% achieved CR
after the second cycle of chemotherapy compared to 9.6% of
patients receiving the high dose liposomal daunorubicin reg-
imen. There was no significant difference in respect to CR
between the groups (p-value = 0.94) (A).21 Considering treat-
ment failure including cases of drug resistance and deaths
during the induction period, there was no significant dif-
ference between the groups (p-value = 0.33) with the leading
cause of death being infections (A).21
Two induction regimens were evaluated in 60- to 83-
year-old patients (mean: 67 years old) with de novo or
secondary AML  and a performance status ≤2 according
to the World Health Organization (WHO) classification.
Daunorubicin (45 mg/m2/day) in 3-h infusions for three days
was compared with daunorubicin (90 mg/m2/day) in 3-h
infusions for three days, both associated with cytarabine
(200 mg/m2/day) in a seven-day continuous infusion followed
by a second cycle where both groups received cytarabine
(1 g/m2) every 12 h for six days. The overall CR was 54% in
the group that received the conventional dose and 64% for the
high-dose group (p-value = 0.002) (A).22
When each cycle was evaluated, the CR rate after the
first cycle using high doses of daunorubicin was better than
in the group that received the conventional dose (52% vs.
35% respectively; p-value <0.001), with no significant differ-
ence after the second cycle. There was also no significantr. 2 0 1 6;3 8(1):58–74
difference between the two groups in respect to hematologic
and non-hematologic toxicity, and mortality after induction
therapy (A).22
Recommendations: There is controversy about the use
of conventional doses and high doses of daunorubicin in
induction therapy in relation to the CR of elderly AML
patients. However, increasing the dose does not increase
the hematological and non-hematological toxicity, or the
number of treatment-related deaths.
What  is  the  number  of  induction  cycles  (1  or  2)
that  is  the  most  effective  in  the  induction  of
acute  myeloid  leukemia  patients?
P – Patients undergoing induction treatment for AML
I – One cycle of chemotherapy
C – Two cycles of chemotherapy
O – Complete remission rate, overall survival, and disease-
free survival
Under 65-year-old adult patients with de novo AML  stratified
into two induction therapy groups – idarubicin (12 mg/m2/day)
for three days or high-dose daunorubicin (50 mg/m2/day)
for five days, both regimens associated with cytarabine
(100 mg/m2/day) as a seven-day continuous infusion, had sim-
ilar CR after the first cycle (64.1% vs. 61.1%; p-value = 0.39).
If the patient did not achieve CR after the first cycle, the
same regimen was repeated at a 3- to 4-week interval which
increased the overall CR rate to 77.9% (78.2% for idarubicin and
77.5% for daunorubicin; p-value = 0.79) (A).6
Regimens using daunorubicin (80 mg/m2/day) for three
days (DNR), idarubicin (12 mg/m2/day) for four days (IDA4), and
idarubicin (12 mg/m2/day) for three days (IDA3), all associated
with cytarabine (200 mg/m2/day) in a seven-day continuous
infusion were compared in 50- to 70-year-old patients. There
was an overall CR rate of 66% with no significant difference
between the groups (61% DNR, 67% IDA4, and 70% IDA3; p-
value = 0.25). However, when patients received a second cycle
of mitoxantrone (12 mg/m2/day) for two days associated with
cytarabine (1 g/m2/day) in 1-h infusions every 12 h for four
days, the CR rate increased to 77% with a significant dif-
ference (p-value = 0.04) between the three groups (70%, 78%
and 83% for the DNR, IDA4 and IDA3 arms, respectively)
(A).7
Three induction regimens were compared in 15- to 60-
year-old patients with primary or secondary AML  and with
no evidence of severe heart, pulmonary, neurological or
metabolic disease or uncontrolled infection, and with nor-
mal  hepatic and renal function. The CR rate was 63.6% after
an induction cycle of daunorubicin (50 mg/m2/day) or mitox-
antrone (12 mg/m2/day) or idarubicin (10 mg/m2/day) on Days
21, 3 and 5 associated with cytarabine (100 mg/m /day) in a
ten-day continuous infusion and etoposide (100 mg/m2/day)
in 1-h infusions for five days. In cases of partial response,
a second cycle was administered with the same drug as the
oter. 
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rst cycle, and the CR rate increased to 68.5%, with no signif-
cant difference between the treatment arms (mitoxantrone
s. daunorubicin: p-value = 0.63; idarubicin vs. daunorubicin:
-value = 0.49) (A).23
A large number of over 18-year-old, treatment-naive
atients with de novo or secondary AML  was assessed after
eing grouped in several therapeutic induction schemes:
ytarabine (100–200 mg/m2/day) as a continuous infusion
ssociated with daunorubicin (45–60 mg/m2/day), idarubicin
12 mg/m2/day) or mitoxantrone (12 mg/m2/day). The overall
R rate was 64%; 74% of the total entered into remission after
he first induction cycle and 26% of the remaining after the
econd cycle; this represents a 16.5% increase in the CR after
he second cycle of induction chemotherapy (p-value = 0.001)
A).23
Recommendations: It is common to perform a second
induction cycle of chemotherapy in patients with AML
who  have 5% or more  blasts in the bone marrow 10–14
days after the first cycle; the complete response rate
increases significantly after the second chemotherapy
cycle.
hat  dose  of  cytarabine  (400  mg/m2 or  1 g/m2
r  1.5  g/m2 or  3  g/m2)  is  the  most  effective  in  the
onsolidation  treatment  of  young  acute  myeloid
eukemia  patients?
P – Patients undergoing induction treatment for AML
I – Use of cytarabine (400 mg/m2/day, 1 g/m2, 1.5 g/m2 or
3 g/m2)
C –
O – Complete remission rate, overall survival, and disease-
free survival
Young patients (16–60 years with a mean of 47 years old)
ith de novo or secondary AML  were evaluated for OS and
isease-free survival (DFS) using different doses of cytarabine
uring consolidation treatment.
All patients took the same drugs during the induction
hase and those who  achieved CR were stratified according to
rognostic factors by cytogenetics. High-risk or intermediate-
isk patients with matched donors were referred for allogeneic
one marrow transplantation. However, low-risk patients and
hose who  did not have HLA-compatible donors were submit-
ed to consolidation.
Consolidation chemotherapy was performed in 52% of
he patients who  were in CR after two cycles of induction.
ytarabine (1 g/m2) every 12 h for six days (total 12 g/m2)
r cytarabine (3 g/m2) every 12 h for six days (total 36 g/m2)
as administered associated with mitoxantrone 10 g/m2 for
hree days in both cases. There was no significant differ-
nce in the non-hematological grade 3 and 4 toxicity between
he two groups. However, the group that received 36 g/m2 of
ytarabine presented neutropenia (24 days – 95% CI: 22–26
ays) longer than the group taking 12 g/m2 (18 days – 95%2 0 1 6;3 8(1):58–74 63
CI: 17–19 days; p-value = 0.004), but there was no difference
in the infectious complications rate between groups (A).24
Patients who used the highest dose of cytarabine required
more  red blood cell transfusions (8 vs. 6; p-value = 0.03),
but there was no difference in the need for platelet con-
centrate transfusions (A). 24 In the analysis of intention to
treat, the estimated 5-year OS was 30% (95% CI: 25–35%) for
the group that received intermediate-dose cytarabine and
33% (95% CI: 28–38%) for the group that received high-dose
cytarabine (p-value = 0.77). The 5-year DFS was estimated at
37% (95% CI: 31–44%) for the intermediate-dose group and
38% (95% CI: 31–45%) for the high-dose group (p-value = 0.86)
(A).24
Two different consolidation chemotherapy regimens were
compared in 15- to 60-year-old patients with de novo AML
(except promyelocytic leukemia) with favorable cytogene-
tics, who received one or two induction cycles and achieved
CR. Arm 1 of the trial was mitoxantrone (12 mg/m2/day)
on Days 1–3, cytarabine (500 mg/m2/day) on Days 1–3 and
on Days 8–10 and etoposide (200 mg/m2/day) on Days 8–10.
Arm 2 comprised cytarabine (3 g/m2/day) on Days 1, 3 and 5
for four cycles followed by maintenance with daunorubicin
(45 mg/m2/day) on Day 1 and cytarabine (100 mg/m2/day) on
Days 1–5.
Relapse occurred in 52% of patients submitted to consoli-
dation therapy; 51.6% in Arm 1 and 48.3% in Arm 2 (mean time:
9.9 months vs. 10.7 months, respectively) (A).25 DFS was 13.7
months (95% CI: 11.3–22.5 months) in Arm 1 and 23.3 months
(95% CI 15.7–47 months) in Arm 2, with the 5-year disease-free
survival (DFS) being 6% higher in Arm 2 (p-value = 0.24). The OS
was 55.6 months in Arm 1 and 62.9 months in Arm 2, with a
5-year OS 2% higher in Arm 2 (p-value = 0.82). Thus, there was
no significant difference between the two arms in respect to
the cumulative incidence of relapse and mortality related to
consolidation therapy (A).25
Arm 1 was associated with greater non-hematological
grade 3 or 4 toxicity compared to Arm 2 (maximum percent-
ages: diarrhea 24% vs. 3%, nausea/vomiting, 26% vs. 3%,  and
serious infection 39% vs. 19%, respectively). Severe heart and
lung side effects were observed mainly in Arm 1. Concerning
hematological toxicity, patients in Arm 2 received more  trans-
fusions than Arm 1 due to repeating cycles of chemotherapy
(A).25
Two consolidation therapies were evaluated in 15- to 65-
year-old patients with AML, including those with promyelo-
cytic leukemia. Group A received cytarabine (100 mg/m2/day)
in a seven-day continuous infusion and Group B received
cytarabine (3 g/m2) in 1-h infusions every 12 h for six days,
both associated with daunorubicin (45 mg/m2/day) for three
days. The cytogenetic risk was not classified and all patients
achieved CR after two induction chemotherapy cycles. The
toxicity, DFS and OS were evaluated.
Grade 3 and 4 toxicity was 36.6% higher in Group B (NNH: 3;
p-value <0.0001), mainly as infections, gastrointestinal disor-
ders (nausea, vomiting or diarrhea) and neurological disorders
(ataxia, stroke or disorientation). The DFS was 10.8 months for
Group A and 12.2 months for Group B (p-value = 0.18), while the
OS was 24.6 months in Group A and 32.6 months in Group B
(p-value = 0.07), with no significant difference when the groups
were followed up for 2, 3 and 5 years (A).26
mote64  rev bras hematol he
Of 693 over 16-year-old patients with de novo AML in first CR
after induction with cytarabine and daunorubicin at standard
doses, 596 were randomized to one of three regimens of
four consolidation cycles. The first group received cytarabine
(100 mg/m2/day) by continuous intravenous infusion for five
days, the second received cytarabine (400 mg/m2/day) by con-
tinuous infusion for five days, and the third group received
cytarabine (3 g/m2) in a 3-h infusion every 12 h on Days 1, 3 and
5. Over a 52-month follow-up, the probability of survival in CR
for under 60-year-old patients was 24% for the 100 mg/m2/day
cytarabine group, 29% for the 400 mg/m2/day cytarabine group
and 44% for the 6 g/m2/day cytarabine group (p-value = 0.002)
(A).27
Recommendations: There is no significant difference
between different doses of cytarabine in the consol-
idation therapy of AML  in respect to DFS and OS.
However, the study that compared standard-dose cytara-
bine (100 mg/m2/day) with high dose (6 g/m2/day) did
not inform the cytogenetic risk. There are no studies
comparing doses of 1 g/m2/day, 1.5 g/m2/day, 2 g/m2/day
and 3 g/m2/day. The total dose of 6 g/m2/day for three
days seems to be associated with greater hematologic
toxicity, and compared with the standard regimen of
100 mg/m2/day, it is also associated with higher non-
hematologic toxicity.
What  dose  of  cytarabine  (400  mg/m2/day,
2  g/m2/day,  3  g/m2/day,  4  g/m2/day  or
6 g/m2/day)  is  the  most  effective  in
consolidating  young  acute  myeloid  leukemia
patients  with  favorable  prognosis  [<60  years,
leukocyte  count  at  diagnosis  <30,000  or
<50,000/mm3 with  cytogenetics:
t(8;21)/AML1-ETO/RUNX1-RUNX1T1,
inv(16)/t(16;16)/CBFbeta/MYH11,  core  binding
factor  leukemia,  FLT3-negative  or
FLT3-ITD-negative/NPM1-mutated]?
P – AML  patients with favorable prognosis [<60 years,
with white blood cell count at diagnosis <30,000 or
<50,000/mm3 with cytogenetics t(8;21)/AML1-ETO/RUNX1-
RUNX1T1, inv(16)/t(16;16)/CBFbeta/MYH11, core binding
factor leukemia, FLT3-negative or FLT3-ITD-negative/NPM1-
mutated]
I – Use of cytarabine (400 mg/m2, 2 g/m2/day, 3 g/m2/day
4 g/m2/day, or 6 g/m2/day)
C –
O – Complete remission rate, overall survival, and disease-
free survival
Patients (16–60 years; mean of 47 years) with de novo or
secondary AML  were evaluated for OS and DFS using differ-
ent doses of cytarabine during consolidation treatment. All
patients had the same regimen during induction and those
who  achieved CR were stratified by prognosis according tor. 2 0 1 6;3 8(1):58–74
cytogenetics. High-risk and intermediate-risk patients who
had HLA-compatible donors were referred for allogeneic bone
marrow transplantation. Low-risk patients and those who  had
no compatible donor underwent consolidation chemotherapy.
Consolidation chemotherapy was administered to 52% of
the patients who were in CR after two induction cycles. The
regimens used were cytarabine 1 g/m2 every 12 h for six days
(total 12 g/m2) or cytarabine 3 g/m2 every 12 h for six days (total
36 g/m2), both associated with mitoxantrone 10 g/m2/day for
three days.
There was no significant difference in the non-
hematological grade 3 and 4 toxicity between the two
groups. However, the group that received 36 g/m2 presented
neutropenia longer than the group of patients who received
12 g/m2 [24 days (95% CI: 22–26) vs. 18 days (95% CI: 17–19);
p-value = 0.004]. However, there was no difference in the infec-
tious complications rate between the two groups. Patients
who used the highest dose of cytarabine required more  red
blood cell transfusions (8 vs. 6; p-value = 0.03) but there was no
difference in the need for platelet concentrate transfusions
(A).24
Chemotherapy consolidation was evaluated in 15- to 60-
year-old patients with de novo AML (except promyelocytic
leukemia) with favorable cytogenetics, who  received one or
two chemotherapy induction cycles and achieved CR. Two dif-
ferent groups were compared. Arm 1 received mitoxantrone
12 (mg/m2/day) on Days 1–3 associated with cytarabine
(500 mg/m2/day) on Days 1–3 and etoposide (200 mg/m2/day)
on Days 8–10 associated with cytarabine (500 mg/m2/day)
also on Days 8–10. Arm 2 received cytarabine (3 g/m2/day)
on Days 1, 3 and 5 for four cycles followed by maintenance
with daunorubicin (45 mg/m2/day) on Day 1 and cytarabine
(100 mg/m2/day) on Days 1–5.
Fifty-two percent of patients who were submitted to con-
solidation therapy relapsed, 51.6% in Arm 1 and 48.3% in Arm
2 (9.9 months vs. 10.7 months, respectively). The mean DFS
was 13.7 months (95% CI: 11.3–22.5 months) in Arm 1 and 23.3
months (95% CI: 15.7–47 months) in Arm 2, with a 5-year DFS
6% higher in Arm 2 (p-value = 0.24). The OS was 55.6 months in
Arm 1 and 62.9 months in Arm 2, with the 5-year OS being 2%
higher in Arm 2 (p-value = 0.82). Thus, there was no significant
difference between the two arms in respect to the cumula-
tive incidence of relapse and mortality related to consolidation
(A).25
Arm 1 had more  non-hematological grade 3 or 4 toxicity
than Arm 2: diarrhea 24% vs. a maximum of 3% in each cycle,
respectively, nausea/vomiting 26% vs. a maximum of 3% in
each cycle, respectively, and severe infection 39% vs. no more
than 19% in each cycle, respectively. Severe cardiac and pul-
monary effects were observed mainly in Arm 1. In regards to
hematological toxicity, patients in Arm 2 received more  trans-
fusions than those in Arm 1 due to the repeating cycles of
chemotherapy (A).25
Young 15- to 64-year-old patients with de novo AML  (except
promyelocytic leukemia according to the FAB classification),
that after one or two chemotherapy induction cycles achieved
CR were divided into two consolidation treatment groups. The
first received high-dose cytarabine repeated for three cycles
and the second a standard dose of cytarabine for four cycles.
The mean follow-up was 48 months (range: 5–78 months).
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The high-dose group received 2 g/m2 in 3-h infusions every
2 h (total 4 g/m2) for five days with each cycle starting one
eek after the recovery of neutrophil, leukocyte, and platelet
ounts to more  than 1.5 × 109/L, 3.0 × 109/L and 100.0 × 109/L,
espectively. The standard-dose group included several regi-
ens: mitoxantrone (7 mg/m2/day) as 30-min infusions
or three days or daunorubicin (50 mg/m2/day) as 30-min
nfusions for three days, or aclarubicin (20 mg/m2/day) as 30-
in  infusions for five days or etoposide (100 mg/m2/day) as 1-h
nfusions for five days, together with vincristine (0.8 mg/m2)
olus on Day 8 and vindesine (2 mg/m2) bolus on Day 10.
ll the above regimens were associated with cytarabine
200 mg/m2/day) as a 24-h continuous infusion for five days.
ach consolidation cycle was started as soon as possible after
he recovery of the neutrophil, leukocyte and platelet counts.
The 5-year DFS for the high-dose and standard-dose groups
ere 43% and 39%, respectively (p-value = 0.724). However,
hen patients with favorable cytogenetics were evaluated
lone, the DFS was 18% higher in the high-dose group (p-
alue = 0.05). There was no significant difference in the 5-year
S between the consolidation regimens for the total group
f patients or for patients with favorable cytogenetics (p-
alue = 0.954 and p-value = 0.174, respectively) (A).28
When cytarabine 100 mg/m2/day as a seven-day continu-
us infusion was compared with cytarabine 3 g/m2 every 12 h
s a continuous infusion for six days, both associated with
aunorubicin 45 mg/m2/day for three days, there was greater
rade 3 and 4 toxicity (infection, gastrointestinal effects, and
eurological effects) in the high-dose group (p-value = 0.0001).
owever, there was no significant difference between the two
roups in respect to the mean OS and DFS of 15- to 65-year-
ld patients with de novo AML  during a follow-up of 85 months
A).26
Recommendations: The overall survival and disease-free
survival of 15- to 65-year-old AML  patients with a favor-
able prognosis does not improve using a higher dose of
cytarabine in the consolidation regimen. However, hema-
tological and non-hematological grade 3 and 4 toxicity
increases as the dose increases.
hat  dose  of  cytarabine  (400  mg/m2/day,
 g/m2/day,  3  g/m2/day,  4  g/m2/day  or
 g/m2/day)  is  the  most  effective  in  the
onsolidation  of  young  acute  myeloid  leukemia
atients  with  poor  or  intermediate  prognosis
leukocyte  count  at  diagnosis  ≥30,000/mm3,
omplex  karyotypes  (≥3  chromosomal
bnormalities),  secondary  acute  myeloid
eukemia,  changes  in  chromosome  3  or  7]?
P – AML  patients with poor or intermediate prognosis [≤60
3years, with white blood cell count at diagnosis ≥30,000/mm ,
complex karyotypes (≥3 chromosomal abnormalities), sec-
ondary AML, changes in chromosome 3 or 7) undergoing
consolidation therapy.2 0 1 6;3 8(1):58–74 65
I – Use of cytarabine (400 mg/m2/day, 2 g/m2/day, 3 g/m2/day,
4 g/m2/day, or 6 g/m2/day)
C –
O – Complete remission rate, overall survival, and disease-
free survival
Young patients, aged 15–64 years old, with de novo AML
(except promyelocytic leukemia by the FAB classification), who
achieved CR after one or two chemotherapy induction cycles
were divided into two groups for consolidation therapy. The
high-dose group received high doses of cytarabine repeated for
three cycles and the standard-dose group received standard
doses of cytarabine for four cycles. Patients were evaluated
over a mean follow-up period of 48 months (range: 5–78
months).
The high-dose group received 2 g/m2 in 3-h infusions every
12 h for five days with each cycle starting one week after
neutrophil, leukocyte and platelet counts recovery to more
than 1.5 × 109/L, 3.0 × 109/L and 100.0 × 109/L respectively. The
standard-dose group received several regimens: mitoxantrone
(7 mg/m2/day) in a 30-min infusion for three days or daunoru-
bicin (50 mg/m2/day) in a 30-min infusion for three days, or
aclarubicin (20 mg/m2/day) in a 30-min infusion for five days
or etoposide (100 mg/m2/day) in a 1-h infusion for five days
together with vincristine (0.8 mg/m2) bolus on Day 8 and vin-
desine (2 mg/m2) bolus on Day 10. All of the above regimens
were associated with cytarabine (200 mg/m2/day) as a 24-h
continuous infusion for five days. Each consolidation cycle was
started as soon as possible after the recovery of the neutrophil,
leukocyte and platelet counts.
The 5-year DFS for the high-dose and standard-dose groups
were 43% and 39%, respectively (p-value = 0.724). However,
when patients with intermediate prognosis were evaluated
alone, the 5-year DFS was 38% for the high-dose group and 39%
for the standard-dose group (p-value = 0.403) and the 5-year OS
were 53% and 54%, respectively (p-value = 0.482). For patients
with unfavorable cytogenetics, the 5-year DFS was 19% higher
in the high-dose group (33% vs. 14%; p-value = 0.364) and the
5-year OS were 39% (high-dose) and 21% (standard-dose) (p-
value = 0.379) (A).28
Two other consolidation regimens (IcE and ICE) were
evaluated in 15- to 60-year-old patients with de novo AML
(except promyelocytic leukemia) who achieved CR after one
or two induction cycles. The IcE regimen comprises idarubicin
(12 mg/m2/day) on Days 1 and 2 associated with cytarabine
(100 mg/m2/day) in a continuous infusion on Days 1–5 and
etoposide (75 mg/m2/day) in a 1-h infusion on Days 1–7.
ICE comprises idarubicin (9 or 12 mg/m2) bolus on Days 1–3
associated with cytarabine (3 g/m2) as a 3-h infusions every
12 h on Days 1, 3, 5 and 7 and etoposide (75 mg/m2/day) on
Days 1–5.
Of the 202 patients in remission after induction, 103
received ICE and 99 received IcE. The 3-year relapse-free sur-
vival was 49% and 46% for the groups treated with ICE and IcE,
respectively, and the 3-year OS was 61% in the group receiv-
ing ICE and 62% in the group receiving IcE (95% CI: 51–71%
vs. 52–71%, respectively); there was no significant difference
between the groups. There was no difference in response
between the two consolidation schemes in any of the risk
subgroups determined by cytogenetics (A).29
66  rev bras hematol hemote
Recommendation: In the consolidation of 15- to 64-year-
old patients with AML  and intermediate or unfavorable
prognosis, there is no significant difference in overall sur-
vival or disease-free survival using the different doses of
I – Chemotherapycytarabine evaluated.
Which  chemotherapy  regimen  (cytarabine  with
or without  anthracycline  and  dose  of
cytarabine)  is  the  most  effective  in  the
consolidation  of  elderly  acute  myeloid
leukemia  patients  (>60  years)?
P – Elderly patients (>60 years) with AML  undergoing consol-
idation treatment
I – Cytarabine with anthracycline
C – Cytarabine without anthracycline
O – Complete remission rate, overall survival, and disease-
free survival
Over 60-year-old patients (61–87 years) with primary or
secondary AML  (excluding those with severe comorbidi-
ties) were followed up for a median of 68 months. Patients
received two induction cycles of cytarabine (100 mg/m2/day)
in a seven-day continuous infusion, associated with daunoru-
bicin (45 mg/m2/day) on Days 3–5, and a consolidation cycle
of cytarabine (1 g/m2) every 12 h on Days 1–5 and ansacrine
(100 mg/m2/day) on Days 1–5. The OS and DFS were 9.7% and
14%, respectively (B).30
After induction therapy with cytarabine (100 mg/m2/day)
as a seven-day continuous infusion and daunorubicin
(45 mg/m2/day) or idarubicin (12 mg/m2/day) for three days,
AML  patients in CR received consolidation treatment with
cytarabine (100 mg/m2) every 12 h for five days, thioguanine
(100 mg/m2) orally every 12 h for five days and daunoru-
bicin (50 mg/m2) or idarubicin (15 mg/m2) on the first day of
chemotherapy. The cycles were repeated at 3- to 4-week inter-
vals for three cycles. Over 60-year-old Patients had a mean OS
of 235 days in the group that received idarubicin in their con-
solidation regimen and 209 days in the group that received
daunorubicin, with no significant difference between the two
groups (p-value = 0.58) (A).11
Elderly patients (55–75 years old) with de novo AML, exclud-
ing those diagnosed with myeloproliferative syndromes, were
evaluated after induction therapy with cytarabine associated
with daunorubicin or idarubicin, and consolidation ther-
apy with cytarabine (50 mg/m2/day) subcutaneously for five
days together with daunorubicin (30 mg/m2/day) or idarubicin
(8 mg/m2/day) for three days. There was no significant differ-
ence between the two groups in respect to non-hematological
toxicity, including sepsis and infectious complications, except
for fever that was higher in the group of patients who received
idarubicin (p-value = 0.001). The three-year DFS was signif-
icantly higher (p-value = 0.016) in the group that received
idarubicin rather than daunorubicin (mean of 647 days vs. 283
days) in the subgroup of 65- to 75-year olds (A).8
Cytarabine (1 g/m2) as a 1-h continuous infusion every 12 h
for four days associated with daunorubicin (80 mg/m2/day) orr. 2 0 1 6;3 8(1):58–74
idarubicin (12 mg/m2/day) on Day 1 of the first cycle and Days
1 and 2 of the second cycle were administered in 50- to 70-
year-old patients with de novo AML (except AML M3  according
to the FAB classification). The estimated event-free survival
at two years was 23.5% (95% CI: 19.5–28%) and at four years
it was 18% (95% CI: 14–22%). The median OS was 17 months,
with estimates for two years of 38% (95% CI: 34–44%) and four
years of 26.5% (95% CI: 22–32%) (A).7
Of 416 patients aged 65 years or older (median: 72 years)
with de novo or AML secondary to MDS (FAB: refractory ane-
mia  with excess blasts in transformation – RAEB-T), 236
achieved CR after induction with cytarabine (200 mg/m2/day)
for seven days and daunorubicin (45 mg/m2/day) or idarubicin
(9 mg/m2/day) for four days. If a CR was not achieved by the
first induction cycle, a second cycle of cytarabine (500 mg/m2)
was infused over 1 h every 12 h for three days associated with
mitoxantrone (12 mg/m2) every 12 h for two days. Granulocyte-
colony stimulating factor was used from Day 9 of treatment
until recovery of the bone marrow. Among patients in CR,
164 were randomized between two consolidation groups. The
first regimen consisted of one cycle similar to the induc-
tion regimen and the second comprised six monthly cycles
of daunorubicin (45 mg/m2) or idarubicin (9 mg/m2) on Day 1
and cytarabine (60 mg/m2) subcutaneously every 12 h on Days
1–5. Multivariate analysis showed that the chance of staying
alive and in CR were 1.59 and 1.51 times higher for the group
receiving six cycles with low-dose cytarabine (p-value = 0.04
and p-value = 0.05, respectively) (A).4
Of 693 over 16-year-old patients with de novo AML in first
CR after induction with standard doses of cytarabine and
daunorubicin, 596 were randomized to one of three regimens
of four consolidation cycles. The first group received Cytara-
bine (100 mg/m2/day) by continuous intravenous infusion for
five days, the second received Cytarabine (400 mg/m2/day) by
continuous infusion for five days, and the third group received
3 g/m2) in a 3-h infusion every 12 h on Days 1, 3 and 5. After a
follow-up of 52 months, the probability of CR for over 60-year-
old patients was 16% or less for the three cytarabine groups
(p-value = 0.19) (A).27
Recommendations: There is no consensus on the best
consolidation strategy for elderly patients.
Is  allogeneic  transplant  more  effective  than
chemotherapy  in  the  consolidation  of  young
acute  myeloid  leukemia  patients  with  favorable
prognoses  and  with  unfavorable  or
intermediate  prognoses?
P – Young patients with AML favorable, intermediary or unfa-
vorable prognosis undergoing consolidation treatmentC – Allogeneic transplantation
O – Complete remission rate, overall survival, and disease-
free survival
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The majority of patients with AML, who achieve CR, relapse
fter conventional chemotherapy. So far, allogeneic bone mar-
ow transplantation (BMT) is considered the only curative
reatment. This procedure influences the OS, but depends
n the existence of an HLA-compatible donor and is asso-
iated with considerable morbidity and mortality. In this
cenario, the definition of to whom receives and when allo-
eneic transplant is indicated becomes an important issue in
he management of AML  patients; cytogenetic and molecular
actors guide this decision.
A randomized study published by the European Group
howed that 16- to 67-year-old patients with advanced MDS  or
DS  transforming into AML, or AML  secondary to MDS with
ntermediate or unfavorable cytogenetics after 83 months of
ollow-up, who underwent one or two induction cycles fol-
owed by a consolidation cycle with idarubicin 10 mg/m2/day
n Days 4–6 and cytarabine 500 mg/m2 as a 2-h infusion every
2 h on Days 1–6 were divided into two groups after CR.
atients in first remission who had HLA-compatible donors
nderwent allogeneic BMT  and those without compatible
onors were submitted to a second consolidation cycle fol-
owed by autologous BMT.  The results were better for patients
ho  performed allogeneic BMT  with a hazard ratio (HR) in
ultivariate analysis of 0.58 (99% CI: 0.22–1.5; p-value = 0.14)
or OS and 0.46 (95% CI: 0.22–1.5; p-value = 0.08) for DFS (A).31
In a meta-analysis, Koreth et al. evaluated the DFS and OS
f under 60-year-old AML  patients with favorable, interme-
iate and unfavorable cytogenetics submitted to allogeneic
MT  in the first CR after starting chemotherapy compared
o patients who  continued in chemotherapy. After a follow-
p of 19–222 months, no benefit was seen in relation to
FS for the AML  group with favorable cytogenetics (HR: 1.06;
5% CI: 0.80–1.42), however the results were better after allo-
eneic BMT  compared to chemotherapy alone for patients
ith intermediate (HR: 0.76; 95% CI: 0.68–0.85) and unfavor-
ble cytogenetics (HR: 0.69; 95% CI: 0.57–0.84) (A). 32 The OS
as better after BMT  compared to chemotherapy alone for
he intermediate cytogenetics (HR: 0.83; 95% CI: 0.74–0.93) and
nfavorable cytogenetics groups (HR: 0.73; 95% CI: 0.59–0.90),
ut not for the favorable cytogenetics group (HR: 1.07; 95% CI:
.83–1.38) (A).32
The German group monitored 18- to 60-year-old patients
ith de novo or secondary AML  and trisomy 8 (+8) alone or
ith an additional aberration, except t(8;21), inv(16), t(16;16),
(15;17), 11q23 abnormalities or complex karyotypes, who
eceived two cycles of induction chemotherapy, followed by
a) high-dose cytarabine (60%), (b) autologous BMT (14%), or (c)
llogeneic BMT  (16%) (A).33 The patients who were submitted
o allogeneic BMT  were younger than the other two groups
32 (range: 18–55) vs. 51 (range: 19–59) years; p-value = 0.001]
ut there was no significant difference in the OS between
he different consolidation treatment strategies. The 3-year
S rate was 37% (95% CI: 23–52%) for high-dose cytarabine,
4% (95% CI: 3–65%) for autologous BMT  and 45% (95% CI:
2–68%) for allogeneic BMT  (p-value = 0.63) (A).33 However,
reatment-related mortality was higher for patients submit-
ed to allogeneic BMT  compared to those who were not (27%
s. 4%; p-value = 0.01), despite the 3-year relapse rate being
ower (27% vs. 69%; p-value = 0.002). This lower probability of
elapse was seen in a greater 3-year DFS; 49% (95% CI: 25–72%)2 0 1 6;3 8(1):58–74 67
for those who underwent allogeneic BMT,  23% (95% CI: 0–51%)
for those who received high-dose cytarabine and 28% (95% CI:
14–41%) for those submitted to autologous BMT  (p-value <0.05)
(A).33
Seven hundred and thirty-four 16- to 60-year-old patients
were followed up in the European Organization for Research
and Treatment of Cancer-Gruppo Italiano Malattie Emato-
logiche dell’Adulto (EORTC-GIMEMA) AML-10 study. After one
or two induction treatment cycles, the patients received a con-
solidation chemotherapy cycle, and while under 46-year olds
with HLA-identical donors were submitted to allogeneic BMT,
the remaining patients underwent autologous BMT.  The 4-
year DFS was 52.2% for patients who underwent allogeneic
BMT  compared to 42.2% for those submitted to autologous
BMT  (HR: 0.80; 95% CI: 0.64–0.99; p-value = 0.44). The inci-
dence of relapse was 30.4% for the allogeneic BMT  group
compared to 52.5% after autologous BMT. The OS was 58.3%
vs. 50.8% for allogeneic and autologous BMT,  respectively. The
DFS in patients with or without HLA-identical donors was
similar in patients with low- and intermediate-risk cytogene-
tics. However, the DFS was 43.4% and 18.4% for allogeneic and
autologous BMT, respectively in patients with high-risk cyto-
genetics. This difference was even more  pronounced in young
(15–35 years old) patients (p-value = 0.036) (A).34 Therefore, the
strategy to perform allogeneic BMT early in first CR has led to
better results of survival, especially in younger patients and
those with unfavorable risk cytogenetics (p-value = 0.18) (A).34
Brunet et al. evaluated 16- to 60-year-old patients with AML
(except M3 by FAB classification) with no history of MDS  or
previous use of cytotoxic drugs or radiation. Patients were
submitted to induction therapy with one or two cycles of ICE
chemotherapy [idarubicin (10 mg/m2/day) as 30-min infusions
on Days 1, 3 and 5, cytarabine (100 mg/m2/day) as continu-
ous infusions on Days 1–10 and etoposide (100 mg/m2/day) as
1-h infusions on Days 1–5]. This was followed by a consoli-
dation cycle with intermediate-dose cytarabine (500 mg/m2)
as 2-h infusions every 12 h on Days 1–6 associated with
mitoxantrone (12 mg/m2/day) over 15 min  on Days 4–6 and
then patients were stratified into different intensification
treatments depending on age and cytogenetic risk. Patients
with low-risk cytogenetics received two cycles of cytarabine
(3 mg/m2) as 2-h infusions every 12 h on Days 1, 3 and 5. Allo-
geneic BMT  was performed in under 50-year-old patients with
intermediate- or high-risk cytogenetics and HLA-identical
donors, and autologous BMT  was performed in over 50-year
olds or those without HLA-identical donors. The groups were
evaluated for treatment-related mortality, OS  and DFS.
Treatment-related mortality was 23 ± 9% for allogeneic
BMT;  3 ± 3% for under 50-year olds who underwent autologous
BMT; 23 ± 6% for over 50-year olds submitted to autologous
BMT  and 14 ± 7% for those who received the high-dose cytara-
bine regimen. There was no significant difference between
the different treatment regimens in respect to the 4-year
OS (41 ± 9%, 52 ± 8%, 38 ± 8%, and 61 ± 6%,  respectively). A
significant difference was observed for the DFS only in over 50-
year-old patients who underwent autologous BMT  compared
to those under 50 who also were submitted to autologous BMT
(48% ± 8 vs. 17 ± 9%, respectively; p-value = 0.03) (A).35 In this
study, the DFS in under 50-year-old patients was similar in the
groups submitted to autologous and allogeneic BMT.
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Recommendation: Allogeneic transplant is more  effec-
tive in young patients with HLA-identical donors and
unfavorable or intermediate-risk cytogenetics. Candi-
dates for allogeneic BMT  are defined as individuals in first
complete remission after the initiation of treatment with
unfavorable or intermediate-risk cytogenetics; these
patients have evident improvement in overall survival
rates and disease-free survival. There is no proven benefit
for patients with favorable cytogenetics.
Is  autologous  transplant  more  effective  than
chemotherapy  in  the  consolidation  of  young
acute  myeloid  leukemia  patients  with  favorable
prognosis  and  in  patients  with  unfavorable  or
intermediate  cytogenetic?
P – Young patients with AML  favorable, intermediary or unfa-
vorable prognosis undergoing consolidation treatment
I – Chemotherapy
C – Autologous transplantation
O – Complete remission rate, overall survival, and disease-
free survival
The best strategy after intensification of remission for AML
patients with favorable risk or intermediate risk and without
a compatible bone marrow donor is still widely debated, given
that there is no robust evidence for therapeutic modalities
apart from allogeneic transplantation, which is considered the
only curative alternative.
Nathan et al. published a meta-analysis comparing a
group of patients in first remission submitted to autologous
hematopoietic stem cell transplantation (HSCT) to a group
who  received intensive chemotherapy. Six studies totaling
1044 patients randomized for autologous HSCT or intensive
chemotherapy were included the meta-analysis. The authors
concluded that patients who received autologous HSCT had
better DFS, but the OS was similar in both groups (A).36
Another randomized study evaluated 16- to 67-year old
patients with advanced MDS,  MDS  transforming into AML or
AML  secondary to MDS,  who after achieving CR, received con-
solidation therapy of high-dose cytarabine. Patients who did
not have a HLA-compatible donor were submitted to autol-
ogous HSCT or a second cycle of high-dose cytarabine. The
4-year OS of patients submitted to autologous HSCT or a sec-
ond consolidation cycle of high-dose cytarabine was 37% and
27%, respectively. The HRs in multivariate analysis were 1.22
(95% CI: 0.65–2.27) for OS and 1.02 (95% CI: 0.56–1.85) for DFS
(A).31
Another publication analyzed 18- to 60-year-old patients
with de novo or secondary AML  and trisomy 8 (+8) alone
or with an additional aberration (except t(8;21), inv(16),
t(16;16), t(15;17) abnormality 11q23, or complex karyotype),
who  received two induction cycles, followed by a high-dose
cytarabine (60%), autologous HSCT (14%) or allogeneic HSCT
(16%). There was no significant difference in the OS between
the three regimens. The 3-year OS was 37% (95% CI: 23–52%) for
high-dose cytarabine, 34% (95% CI: 3–65%) for autologous BMTr. 2 0 1 6;3 8(1):58–74
and 45% (95% CI: 22–68%) for allogeneic BMT  (p-value = 0.63)
(A).32 However, the treatment-related mortality was higher
for patients submitted to allogeneic BMT than those of the
other regimens (27% vs. 4%; p-value = 0.01), despite the 3-year
relapse rate being lower (27% vs. 69%; p-value = 0.002). This
lower probability of relapse is seen in the higher 3-year DFS:
49% (95% CI: 25–72%) for those who underwent allogeneic
BMT,  23% (95% CI: 0–51%) for those who received high-dose
cytarabine and 28% (95% CI: 14–41%) for those submitted to
autologous BMT (p-value <0.05) (A).33
Moreth et al., in a systematic review, analyzed 24 clinical
trials involving under 60-year-old patients with de novo or sec-
ondary AML with follow-ups of 1–222 months. Patients with a
HLA-compatible donor after the first CR underwent allogeneic
BMT,  while those without a HLA-compatible donor received
autologous BMT or chemotherapy or both. The three groups
were compared and the HR for relapse and death due to allo-
geneic BMT was 0.80 (95% CI: 0.74–0.86). The allogeneic BMT
procedure provided significant benefits in respect to the DFS
in high-risk (HR 0.69; 95% CI: 0.57–0.84) and intermediate-risk
cytogenetics patients (HR 0.76; 95% CI: 0.68–0.85), but there
was no significant benefit for low-risk patients (HR: 1.06; 95%
CI: 0.80–1.42) (A).32
In a prospective study of 16- to 60-year-old AML  patients
(except M3  by the FAB classification) with no history of MDS
or previous use of cytotoxic drugs or radiation, patients were
stratified by risk related to cytogenetics and age after induc-
tion therapy. Favorable cytogenetics was defined as t(8;21)
and inv(16), and the cut off point for indicating for allogeneic
HSCT was 50 years old. After stratification depending on age
and cytogenetic risk, patients were evaluated for treatment-
related mortality, OS and DFS. Low-risk patients received two
cycles of cytarabine (3 g/m2) as 2-h infusions every 12 h on Days
1, 3 and 5. Under 50-year-old patients with intermediate- or
high-risk cytogenetics and HLA-identical donors were submit-
ted to allogeneic BMT, and over 50-year olds and individuals
without HLA-identical donors underwent autologous BMT.
The treatment-related mortality was 23 ± 9% for allogeneic
BMT,  3 ± 3% for autologous BMT in under 50-year olds and
23 ± 6% for over 50-year olds and 14 ± 7% for those who
received high-dose cytarabine. There was no significant differ-
ence in the 4-year OS between the different regimens (41 ± 9%,
52 ± 8%, 38 ± 8 and 61 ± 6%, respectively). A significant differ-
ence was observed for the DFS only for under 50-year-old
patients who underwent autologous BMT compared to over
50-year olds also submitted to autologous BMT  (48% ± 8 vs.
17 ± 9%, respectively; p-value = 0.03) (A).35 This study found
that age, cytogenetics and white blood cell count at diag-
nosis are the adverse factors most associated with relapse.
Of the low-risk cytogenetics patients who did not receive
transplants, those with t(8;21) had higher DFS than those
with inv(16). In terms of leukemia-free survival, the results
of autologous and allogeneic transplants were similar when
the mortality associated with allogeneic BMT  is considered
(A).35
In an analysis of 16- to 60-year-old patients in the EORTC-
GIMEMA AML-10 study, patients received one consolidation
chemotherapy cycle after one or two induction treatment
cycles. Under 46-year olds with HLA-identical donors were
submitted to allogeneic BMT and the remaining patients
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nderwent autologous BMT.  The 4-year DFS was 52.2% for
atients who  underwent allogeneic BMT  compared to 42.2%
or those submitted to autologous BMT  (HR: 0.80; 95% CI:
.64–0.99; p-value = 0.44)(A).34 The relapse rate was lower in
llogeneic BMT  than in autologous BMT  (30.4% vs. 52.5%,
espectively). The OS was 58.3% vs. 50.8% in allogeneic and
utologous BMT,  respectively (p-value = 0.18) (A).34 The DFS
n patients with or without HLA-identical donors was sim-
lar for those with low- and intermediate-risk cytogenetics.
owever, the DFS was 43.4% and 18.4% for allogeneic and
utologous BMT,  respectively in patients with high-risk cyto-
enetics. This difference was even more  pronounced in young
15–35 years old) patients (p-value = 0.036) (A).34 In this study,
arly allogeneic BMT led to better outcomes in patients with
ntermediate- and high-risk cytogenetics (A).34
Recommendations: Autologous bone marrow transplan-
tation or intensive chemotherapy with cytarabine are
indicated for patients without HLA-compatible donors
or with favorable cytogenetics. However, there is contro-
versy about the best consolidation treatment option for
patients at intermediate risk, who  are not candidates for
allogeneic transplantation.
hat  are  the  complete  remission,  overall
urvival  and  disease-free  survival  rates  for
cute  myeloid  leukemia  patients  with  favorable
ytogenetics  submitted  to  chemotherapy?
P – Adult patients with AML  and karyotype considered favor-
able
I – Chemotherapy
C –
O – Complete remission rate, overall survival, disease-free
survival
Two hundred and seventy-eight 50- to 70-year-old AML
atients were analyzed, 33% (93 patients) of whom had muta-
ions of the NPM1 gene (nucleofosmine 1), and 79 had type A,
 or D mutations. All were previously treated with induction
hemotherapy using daunorubicin (60 mg/m2/day) on Days
–3 and cytarabine (200 mg/m2/day) as a continuous infusion
n Days 1–7. Of the patients with NPM1 mutations, 74.2%
chieved CR and of these, 65.6% were tested for minimal resid-
al disease (MRD); results were positive in 46 and negative in
5 patients. The mutation conferred a 3.66-fold risk of relapse
95% CI: 1.10–12.15; p-value = 0.035), but no significant impact
n the OS of patients (A).37
NPM1-positive and NPM1-negative patients in the group of
LT3-ITD-negative individuals were compared; there was a 7%
ower OS rate (95% CI: 0.2–0.4; p-value <0.001) and an 8% lower
FS rate for NPM1-positive individuals (95% CI: 0.1–0.3; p-value
380.001) (A).
Seventy patients diagnosed with AML  with a mean age of
6 years (23–87 years) treated with fludarabine (30 mg/m2/day)
n Days 1–4, cytarabine (2 g/m2/day) every 12 h on Days 1–42 0 1 6;3 8(1):58–74 69
and idarubicin (12 mg/m2/day) on Days 2–4 were evaluated
for the presence of the NPM1 mutation; 20 patients (29%) had
the mutation. Thirty-six patients (51%) were treated with all
trans-retinoic acid (ATRA) in combination with chemother-
apy. The CR rate was 63% with no difference between patients
with or without the NPM1 mutation (70 vs. 60%; p-value = 0.43)
and there was no significant difference between patients
who received ATRA and those who did not (71% vs. 69%;
p-value = 0.62). The addition of ATRA in the induction ther-
apy did not increase the OS, DFS or event-free survival
(A).39
The MRD was analyzed in 278 AML patients, 163 with
t(8;21) and 115 with inv(16) mutations after induction ther-
apy [AD (cytarabine and daunorubicin), ADE (cytarabine,
daunorubicin and etoposide) or FLAG-Ida (fludarabine, cytara-
bine, idarubicin, and filgrastim)] and after consolidation
[MACE (Amsacrine, cytarabine, and etoposide) or MidAC
(Mitozantrone and cytarabine) or two doses of Ara-C]. Patients
were also randomized to receive gemtuzumab ozogamicin
in the induction and/or consolidation therapy. The aver-
age follow-up was 36 months (range: 2–79 months). The
overall CR for patients with the t(8;21) and inv(16) muta-
tions were 97% and 92%, respectively, and the cumulative
incidences of relapse were 18% and 23%, respectively. The
evaluation of MRD by quantitative reverse transcription poly-
merase chain reaction (RT-PCR) was negative in peripheral
blood and bone marrow samples of 8% of patients with t(8;21)
after induction therapy, in 40% after the consolidation cycles
and 70% after the follow-up. For the inv(16) mutation, the
results were negative in peripheral blood and bone marrow
samples for 6% of the patients after induction, 44% after
three cycles of consolidation and 69% after the follow-up
(A).40
Mutational analysis of 18 genes was carried out in 398
under 60-year-old AML patients who were randomly assigned
to receive high-dose or standard-dose induction therapy with
daunorubicin. At least one somatic change was identified in
97.3% of the patients. Among the changes, positivity for the
CEBP, t(8;21) and inv(16) mutations were associated with
better OS (p-value = 0.05, p-value <0.001 and p-value <0.001,
respectively). The favorable effect of the NPM1 mutation
was restricted to patients with the NPM1 and IDH1 or IDH2
mutations. The 3-year OS for these patients with favorable
cytogenetics was 19%. Patients with the NPM1 mutation sub-
mitted to induction therapy with high-dose daunorubicin had
an OS of 44% compared with 25% of those who received
standard doses (A).41
The molecular profile of 135 AML  patients with nor-
mal  karyotype was evaluated after consolidation treatment
with chemotherapy alone (n = 41) following one autologous
transplantation (n = 40), two autologous transplants (n = 17) or
after allogeneic transplants (n = 37). Forty-six (34%) FLT3-ITD-
negative patients were positive for NPM1 mutations while the
remaining patients had other molecular changes. The mean
follow-up was 86 months (range: 16–118 months). In the uni-
variate analysis, the 4-year leukemia-free survival and OS
were significantly higher in NPM1-positive/FLT3-ITD-negative
patients compared to the group with other molecular changes
(61% vs. 43% and 72% vs. 48%; p-value = 0.02 and p-value = 0.01,
respectively). For the NPM1-positive/FLT3-ITD-negative group,
mote70  rev bras hematol he
there was no benefit with other proposed consolidation regi-
mens (4-year leukemia-free survival of 71% for allogeneic
HSCT, 56% for autologous HSCT and 60% for chemotherapy,
with OS of 73%, 71% and 60%, respectively; p-value > 0.05) (A).42
The response to ATRA associated to daunorubicin, cytara-
bine and thioguanine (DAT) was investigated in the induction
therapy of 1075 non-promyelocytic AML  patients. The NPM1
and CEPBA mutations were identified in 207 and 35 patients,
respectively. The 8-year OS for the group with the NPM1 muta-
tion was 47% when treated with ATRA and 39% without ATRA,
while it was 35% and 47%, respectively for those with the
CEBPA mutation. The 8-year relapse-free survival for the group
with the NPM1 mutation was 42% in the group treated with
ATRA and 37% in the group without ATRA, and with the CEBPA
mutation, it was 28% and 29%, respectively (A).43
Recommendations: The 3-year overall survival (OS) was
19% for adult non-promyelocytic AML  patients with
favorable cytogenetic changes [t(8;21) or inv(16)] using the
different therapeutic modalities. The CR was 97% for the
t(8,21) mutation and 92% for inv(16).
In NPM1-positive/FLT3-ITD-negative patients, the CR
ranges from 63% to 74.2%; the 8-year OS ranges from 39%
to 47%. The 4-year leukemia-free survival for patients
with the NPM1 mutation is 61% and at 8 years, it is
37–42%.
For the CEBP mutation, the 8-year OS ranges from 35% to
47% and leukemia-free survival ranges from 28% to 29%.
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Appendix  A.
PICO 1
Which anthracycline agent is the most effective in inducing
remission of acute myeloid leukemia?
P – Patients undergoing induction treatment for AML
I – Anthracycline agent (daunorubicin, doxorubicin,
idarubicin)
C –
O  – Complete remission rate, overall survival, and
disease-free survival((Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelo-
cytic, Acute OR Promyelocytic) AND (Daunorubicin OR
Doxorubicin OR Idarubicin OR Amsacrine OR Cytarabine)
AND (Therapy/broad[filter] OR Comparative study OR
Comparative studies OR Epidemiologic methods)) = 4530
1st Selection: 11 articlesr. 2 0 1 6;3 8(1):58–74
PICO 2
What  dose (100 mg/m2/day and 200 mg/m2/day) of cytarabine
(Ara-C or Arabinoside-C) is the most effective in the induction
therapy of acute myeloid leukemia patients?
P – Patients undergoing induction treatment for AML
I – Cytarabine or Ara-C or Arabinoside-C – 100 mg/m2/day
C – Cytarabine or Ara-C or Arabinoside-C – 200 mg/m2/day
O – Complete remission rate, overall survival, and
disease-free survival
((Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelo-
cytic, Acute OR Promyelocytic) AND (Daunorubicin OR
Doxorubicin OR Idarubicin OR Cytarabine) AND (Ther-
apy/broad [filter] OR Comparative study OR Comparative
studies OR Epidemiologic methods)) = 4530
1st Selection: 5 articles
PICO 3
What  dose of daunorubicin (45, 60 or 90 mg/m2/day) is
the most effective for induction therapy of acute myeloid
leukemia in young patients (<60 years)?
P – Under 60-year-old patients undergoing induction
treatment for AML
I – Daunorubicin (45, 60 or 90 mg/m2/day)
C – Daunorubicin (45, 60 or 90 mg/m2/day)
O – Complete remission rate, overall survival, and
disease-free survival
((Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelo-
cytic, Acute OR Promyelocytic) AND (Daunorubicin OR
Doxorubicin OR Idarubicin OR Amsacrine OR Cytarabine)
AND (Therapy/broad[filter] OR Comparative study OR
Comparative studies OR Epidemiologic methods)) = 4533
1st Selection: 3 articles
PICO 4
What  dose of daunorubicin (45, 60 or 90 mg/m2) is the most
effective for induction therapy of acute myeloid leukemia in
elderly patients (>60 years)?
P – Over 60-year-old patients undergoing induction treat-
ment for AML
I – Daunorubicin (45, 60 or 90 mg/m2)
C – Daunorubicin (45, 60 or 90 mg/m2)
O – Complete remission rate, overall survival, and
disease-free survival
((Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelo-
cytic, Acute OR Promyelocytic) AND (Daunorubicin OR
Doxorubicin OR Idarubicin OR Amsacrine OR Cytarabine)
AND (Therapy/broad[filter] OR Comparative study OR
Comparative studies OR Epidemiologic methods)) = 4533
1st Selection: 2 articles
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ICO 5
 What  is the number of induction cycles (1 or 2) that is the
ost effective in the induction of acute myeloid leukemia
atients?
 – Patients undergoing induction treatment for AML
 – One cycle of chemotherapy
 – Two cycles of chemotherapy
 – Complete remission rate, overall survival, and disease-
ree survival
(Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelo-
ytic, Acute OR Promyelocytic) AND (Daunorubicin OR
oxorubicin OR Idarubicin OR Amsacrine OR Cytarabine)
ND (Therapy/broad[filter] OR Comparative study OR
omparative studies OR Epidemiologic methods)) = 4533
st Selection: 4 articles
ICO 6
hat  dose of cytarabine (400 mg/m2 or 1 g/m2 or 1.5 g/m2 or
 g/m2) is the most effective in the consolidation treatment of
oung acute myeloid leukemia patients?
 – Patients undergoing induction treatment for AML
 – Use of cytarabine (400 mg/m2/day, 1 g/m2, 1.5 g/m2 or
 g/m2)
 –
 – Complete remission rate, overall survival, and disease-
ree survival
(Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelocytic,
cute OR Promyelocytic) AND (Daunorubicin OR Doxoru-
icin OR Idarubicin OR Amsacrine OR Cytarabine) AND
Therapy/broad[filter] OR Comparative study OR Compara-
ive studies OR Epidemiologic methods)) = 4530
st Selection: 3 articles
ICO 7
hat  dose of cytarabine (400 mg/m2/day, 2 g/m2/day,
 g/m2/day, 4 g/m2/day or 6 g/m2/day) is the most effective in
onsolidating young acute myeloid leukemia patients with
avorable prognosis [<60 years, leukocyte count at diagnosis
30,000 or <50,000/mm3 with cytogenetics: t(8;21)/AML1-
TO/RUNX1-RUNX1T1, inv(16)/t(16;16)/CBFbeta/MYH11,
ore binding factor leukemia, FLT3-negative or FLT3-ITD-
egative/NPM1-mutated]?
 – AML  patients with favorable prognosis [<60 years,
ith white blood cell count at diagnosis <30,000 or
50,000/mm3 with cytogenetics t(8;21)/AML1-ETO/RUNX1-
UNX1T1, inv(16)/t(16;16)/CBFbeta/MYH11, Core binding
actor leukemia, FLT3-negative or FLT3-ITD-negative/NPM1-
utated]
 – Use of cytarabine (400 mg/m2, 2 g/m2/day, 3 g/m2/day
 g/m2/day, or 6 g/m2/day) –
 – Complete remission rate, overall survival, and disease-
ree survival2 0 1 6;3 8(1):58–74 71
((Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelocytic,
Acute OR Promyelocytic) AND (Daunorubicin OR Doxoru-
bicin OR Idarubicin OR Amsacrine OR Cytarabine) AND
(Therapy/broad[filter] OR Comparative study OR Compara-
tive studies OR Epidemiologic methods)) = 4530
1st Selection: 4 articles
PICO 8
What  dose of cytarabine (400 mg/m2/day, 2 g/m2/day,
3 g/m2/day, 4 g/m2/day or 6 g/m2/day) is the most effective in
the consolidation of young acute myeloid leukemia patients
with poor or intermediate prognosis [leukocyte count at diag-
nosis ≥30,000/mm3, complex karyotypes (≥3 chromosomal
abnormalities), secondary acute myeloid leukemia, changes
in chromosome 3 or 7]?
P – AML patients with poor or intermediate prognosis [≥60
years, with white blood cell count at diagnosis ≥30,000 or
<50,000/mm3 complex karyotypes (≥3 chromosomal abnor-
malities), secondary AML, changes in chromosome 3 or 7)
undergoing consolidation therapy.
I – Use of cytarabine (400 mg/m2/day, 2 g/m2/day, 3 g/m2/day,
4 g/m2/day, or 6 g/m2/day)
C –
O – Complete remission rate, overall survival, and disease-
free survival
((Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelocytic,
Acute OR Promyelocytic) AND (Daunorubicin OR Doxoru-
bicin OR Idarubicin OR Amsacrine OR Cytarabine) AND
(Therapy/broad[filter] OR Comparative study OR Compara-
tive studies OR Epidemiologic methods)) = 4530
1st Selection: 2 articles
PICO 9
Which chemotherapy regimen (cytarabine with or without
anthracycline and dose of cytarabine) is the most effective in
the consolidation of elderly acute myeloid leukemia patients
(>60 years)?
P – Elderly patients (>60 years) with AML undergoing consol-
idation treatment
I – Cytarabine with anthracycline
C – Cytarabine without anthracycline
O – Complete remission rate, overall survival, and disease-
free survival
((Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelocytic,
Acute OR Promyelocytic) AND (Daunorubicin OR Doxoru-
bicin OR Idarubicin OR Amsacrine OR Cytarabine) AND
(Therapy/broad[filter] OR Comparative study OR Compara-
tive studies OR Epidemiologic methods)) = 4530
1st Selection: 5 articlesPICO 10
Is allogeneic transplant more effective than chemotherapy in
the consolidation of young acute myeloid leukemia patients
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with favorable prognoses and with unfavorable or intermedi-
ate prognoses?
P – Young patients with AML  favorable, intermediary or unfa-
vorable prognosis undergoing consolidation treatment
I – Chemotherapy
C – Allogeneic transplantation
O – Complete remission rate, overall survival, and disease-
free survival
((Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelocytic,
Acute OR Promyelocytic) AND (Daunorubicin OR Doxoru-
bicin OR Idarubicin OR Amsacrine OR Cytarabine) AND
(Therapy/broad[filter] OR Comparative study OR Compara-
tive studies OR Epidemiologic methods)) = 4530
1st Selection: 5 articles
PICO 11
Is autologous transplant more effective than chemotherapy in
the consolidation of young acute myeloid leukemia patients
with favorable prognosis and in patients with unfavorable or
intermediate cytogenetic?
P – Young patients with AML  favorable, intermediary or unfa-
vorable prognosis undergoing consolidation treatment
I – Chemotherapy
C – Autologous transplantation
O – Complete remission rate, overall survival, and disease-
free survival
((Leukemia, Myeloid, Acute) NOT (Leukemia, Promyelocytic,
Acute OR Promyelocytic) AND (Daunorubicin OR Doxoru-
bicin OR Idarubicin OR Amsacrine OR Cytarabine) AND
(Therapy/broad[filter] OR Comparative study OR Compara-
tive studies OR Epidemiologic methods)) = 4530
1st Selection: 6 articles
PICO 12
What  are the complete remission, overall survival and
disease-free survival rates for acute myeloid leukemia
patients with favorable cytogenetics submitted to chemother-
apy?
P – Adult patients with AML  and karyotype considered
favorable
I – Chemotherapy
C –
O  – Complete remission rate, overall survival, disease-free
survival
(Acute Myeloid Leukemia OR Leukemia, Acute Myeloge-
nous OR Leukemia, Myeloblastic, Acute OR Leukemia,
Myelocytic, Acute OR Leukemia, Myelogenous, Acute OR
Leukemia, Nonlymphoblastic, Acute OR Leukemia, Non-
lymphocytic, Acute OR AML) AND (genetic mutation
OR chromosome aberrations OR chromosome abnormal-
ities OR mutation* OR Core Binding Factor alpha Pro-
teins OR Runx Proteins OR Polyomavirus Enhancer A
Binding Protein 2 OR Polyomavirus Enhancer Binding
1r. 2 0 1 6;3 8(1):58–74
Protein 2, Alpha Subunit OR Runt Domain Factor OR Acute
Myeloid Leukemia Proteins OR PEBP2A Transcription Factors
OR Transcription Factors, PEBP2A OR CEBPA OR t(8:21) OR
t(16) OR inv(16) OR inv(16) fusion protein, human OR NPM1
OR FLT3) AND random* = 73
1st Selection: 7 articles
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